Regarding the activation of extracellular TLRs, Diprovocim, a small drug agonist of TLR2, identified through a screening of molecules on macrophages, showed efficacy in combination with anti-PD-L1 antibodies in a melanoma model [130]. Here, TLR2 is linked to melanoma.